Klatskin Tumor: Clinical Trials

18 trials for Klatskin Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 unknown, 3 active not recruiting, 3 recruiting. 18 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 218Completed 6, Unknown 4, Active not recruiting 3, Recruiting 3, Terminated 2
Phase 12Unknown 2
Phase 32Recruiting 1, Unknown 1

Follow Klatskin Tumor: new trials by email Literature Review of Klatskin Tumor trials Research Report on Klatskin Tumor

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Phase 2 / Phase 3RecruitingAmsterdam UMC, location VUmc1502026-04-172026-08-25
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase 2RecruitingJinbo Yue382025-07-012026-10-15
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Gemcitabine Oxaliplatin and 5FU - Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma
Phase 2TerminatedPeking University12024-12-312026-01-28
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
Capecitabine, Toripalimab - Gallbladder Cancer, Hilar Cholangiocarcinoma
Phase 2Active not recruitingTianjin Medical University Cancer Institute and Hospital1102024-11-122024-12-05
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
Binimetinib, Biopsy Procedure, Biospecimen Collection - Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)182024-02-092026-11-12
Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
Phase 2Active not recruitingUniversity of Kansas Medical Center152024-02-012026-02-24
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
PD-1antibody plus GEMOX - Perihilar Cholangiocarcinoma
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University622023-01-312026-02-09
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Phase 2CompletedInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest402022-05-232025-05-01
Biliary Drainage Plus HAIC in Locally Advanced pCCA
oxaliplatin and 5-fluorouracil, Biliary Drainage, Best Supportive Care - Perihilar Cholangiocarcinoma
Phase 2CompletedPeking University1272021-11-012025-12-18
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Toripalimab plus Lenvatinib - Advanced Biliary Tract Cancer
Phase 2UnknownPeking Union Medical College Hospital442020-08-112023-03-29
Fluorescence Image Guided Surgery in Cholangiocarcinoma
Bevacizumab-IRDye800CW, near infrared (NIR) fluorescence imaging - Hilar Cholangiocarcinoma
Phase 1 / Phase 2UnknownUniversity Medical Center Groningen122019-04-012021-04-28
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC294640, Hydroxychloroquine Sulfate 200 MG - Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
Phase 2CompletedRedHill Biopharma Limited652018-03-072025-07-23
Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma
PDT-Deuteporfin(6 hour), PDT-Deuteporfin(9 hour), stenting - Hilar Cholangiocarcinoma
Phase 2TerminatedShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.72017-05-172019-07-17
Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
bilateral metal stent insertion, unilateral metal stent insertion - Hilar Cholangiocarcinoma
Phase 2 / Phase 3UnknownAir Force Military Medical University, China702014-07-012019-08-01
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
Temoporfin - Cholangiocarcinoma, Tumor
Phase 2CompletedChinese University of Hong Kong102014-03-282023-08-22
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis - Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)532014-02-012017-09-12
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
liver transplantation combined with neoadjuvant therapy - Hilar Cholangiocarcinoma
Phase 1 / Phase 2UnknownThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School602013-05-012014-06-30
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Erlotinib Hydrochloride, Sorafenib Tosylate - Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)402010-04-012015-06-30

Narrower conditions

Cholangiocarcinoma (11)  ·  Gallbladder Neoplasms (6)  ·  Bile Duct Neoplasms (3)  ·  Biliary Tract Neoplasms (2)  ·  Carcinoma, Hepatocellular (1)  ·  Cirrhosis, Familial, with Pulmonary Hypertension (1)  ·  Jaundice (1)  ·  Neoplasms (1)

Broader conditions

Adenocarcinoma (18)  ·  Carcinoma (18)  ·  Neoplasms by Histologic Type (18)  ·  Neoplasms, Glandular and Epithelial (18)  ·  Neoplasms (17)  ·  Biliary Tract Diseases (7)  ·  Cholangiocarcinoma (7)  ·  Digestive System Diseases (7)  ·  Digestive System Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Gallbladder Diseases (6)  ·  Biliary Tract Neoplasms (5)  ·  Bile Duct Diseases (3)  ·  Hyperbilirubinemia (1)  ·  Liver Diseases (1)

Interventions

Fluorouracil (4)  ·  Capecitabine (3)  ·  Oxaliplatin (3)  ·  Biopsy (2)  ·  Cisplatin (2)  ·  Gemcitabine (2)  ·  Leucovorin (2)  ·  Magnetic Resonance Spectroscopy (2)  ·  Specimen Handling (2)  ·  dehydroftorafur (2)  ·  toripalimab (2)  ·  3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1)  ·  Erlotinib Hydrochloride (1)  ·  Hydroxychloroquine (1)  ·  Neoadjuvant Therapy (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Peking University (2)  ·  Air Force Military Medical University, China (1)  ·  Amsterdam UMC, location VUmc (1)  ·  Chinese University of Hong Kong (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  Jinbo Yue (1)  ·  Peking Union Medical College Hospital (1)  ·  RedHill Biopharma Limited (1)  ·  Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (1)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)  ·  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)  ·  University Medical Center Groningen (1)  ·  University of Kansas Medical Center (1)

Countries

China (9)  ·  United States (5)  ·  Netherlands (2)  ·  Germany (1)  ·  Hong Kong (1)

Top investigators

Anthony El-Khoueiry (1)  ·  Ardaman Shergill (1)  ·  Bo Zhang (1)  ·  Chao Liu, PhD (1)  ·  G. M. van Dam, MD, PhD (1)  ·  Guohong Han, MD,Ph.D (1)  ·  Haitao Zhao, MD (1)  ·  Jinbo Yue (1)  ·  M. T. de Boer, MD, PhD (1)  ·  Mitesh Borad, MD (1)  ·  Richard Kim (1)  ·  Salah Al-Batran, Prof. Dr. (1)

Results publications

PMID 20375404, PMID 24769639, PMID 24852116, PMID 26179201, PMID 26598942, PMID 27095655, PMID 27234522, PMID 27806234, PMID 28420720, PMID 28818953, PMID 29341833, PMID 29433850, PMID 29882997, PMID 30515783, PMID 30642373, PMID 30646854, PMID 30755690, PMID 30811474, PMID 31081949, PMID 31403867, PMID 31407173, PMID 31501784, PMID 33198671, PMID 42433279

NIH funding

U10CA032102 (2), P30CA168524 (1), U10CA180821 (1), U10CA180888 (1)